Acuta Capital Partners, LLC 89bio, Inc. Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $493,968 - $636,648	32,800 New	32,800 $506,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $6.86 Million - $11 Million	-393,548 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$20.22 - $26.73 $826,027 - $1.09 Million	-40,852 Reduced 9.4%	393,548 $9.32 Million
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $391,404 - $474,552	16,900 Added 4.05%	434,400 $10.6 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $10.2 Million - $16.2 Million	417,500 New	417,500 $10.7 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.